Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Blue Water Ventures International Inc (OP: BWVI )

0.0001 UNCHANGED
Streaming Delayed Price Updated: 10:09 AM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Blue Water Ventures International Inc

Historical Regulatory Filing Deficiences Continue to Stifle Psycheceutical Biosciences
Via ACCESSWIRE
Psycheceutical Bioscience Strategically Pivots Into the Brain-Computer Interface (BCI) Space
Via ACCESSWIRE
Dr. Neilank Jha Appointed as Executive Chairman and Chief Executive Officer of Psycheceutical Bioscience Inc.
Via ACCESSWIRE
Psycheceutical Bioscience Launches Wefunder Crowdfunding Campaign for Safer Psychedelic Dosing
Via ACCESSWIRE
Psycheceutical Announces Successful First Cohort Dosing; Moves to Dose Escalation in Phase I Trial of NeuroDirect Ketamine for PTSD
Via ACCESSWIRE
Psycheceutical Bioscience Announces Completion of PCAOB Audit and Future Corporation Action Strategy
Via ACCESSWIRE
First Patient Dosed in Psycheceutical's Phase I Study Exploring Topical Administration of Ketamine to Treat PTSD
Via ACCESSWIRE
The Next Generation Of Mental Health Treatment: Psycheceutical Bioscience Inc.’s (OTCPK:BWVI) Novel Topical Ketamine Delivery
Via ACCESSWIRE
Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab
Doblin commented on the potential of the company’s NeuroDirect™ ketamine topical cream to help those suffering from PTSD 
From Psycheceutical Bioscience, Inc.
Via GlobeNewswire
What If There Was A Topical Cream That Treated PTSD Without Side Effects? — Psycheceutical Bioscience, Inc (OTCPK: BWVI) Is Pioneering A Possible Solution
By Faith Ashmore, Benzinga 
Via TheNewswire.com
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD
From Psycheceutical Bioscience, Inc.
Via GlobeNewswire
Psycheceutical Bioscience, Inc (OTCPK: BWVI) Could Be Revolutionizing Psychedelic Health Care By Developing The First Ever Topical Psychedelic Cream To Treat PTSD
By Julian Richard, Benzinga 
Via TheNewswire.com
BioMedNewsBreaks – Psycheceutical Bioscience Inc. (BWVI) Inks Agreement for First-Ever Clinical Trials of a Proprietary Ketamine Topical Cream to Treat PTSD
Via Investor Brand Network
Exposures Product Safety
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD
From Psycheceutical Bioscience, Inc.
Via GlobeNewswire
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD
Company intends to pursue 505(b)(2) regulatory pathway for novel topical formulation of ketamine for the treatment of PTSD 
From Psycheceutical Bioscience, Inc.
Via GlobeNewswire
Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD
Topical ketamine formulations could improve the methods of treating post-traumatic stress disorder (PTSD) 
From Psycheceutical Bioscience, Inc.
Via GlobeNewswire
Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer
Renowned neurosurgeon to oversee the development of breakthrough psychedelic therapeutics 
From Psycheceutical Bioscience, Inc.
Via GlobeNewswire
Dr. Aric Logsdon Joins Psycheceutical Bioscience, Inc. as Company’s Scientific Director
Dr. Logsdon’s expertise to help guide the company’s further research and development for its patented drug-delivery technology 
From Psycheceutical Bioscience, Inc.
Via GlobeNewswire
Psycheceutical Bioscience, Inc. Announces Medical Advisory Board
To be led by accomplished Neurosurgeon Dr. Julian Bailes, the Medical Advisory Board will support the Company in developing breakthrough psychedelic medicine technologies for mental health treatments 
From Psycheceutical Bioscience, Inc.
Via GlobeNewswire
Psycheceutical Bioscience, Inc.'s Zappy Zapolin Added to The Benzinga Psychedelics Advisory Council
Chief Visionary Officer of Psycheceutical, Zappy Zapolin, will join other prominent leaders in Psychedelics on Benzinga’s Council Board 
From Psycheceutical Bioscience, Inc.
Via GlobeNewswire
Psycheceutical Completes Acquisition by Blue Water Ventures International
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Blue Water Ventures International, Inc. Signs Non-Binding Letter of Intent to Acquire Psycheceutical, Inc.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Blue Water Ventures International and Partners Endurance Exploration Group Share Update on the Current 2021 Recovery Season of Steamboat Pulaski
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
New Sonar Survey Discovers Large Unsalvaged Sections of SB Pulaski, 1838
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.